Mission Statement, Vision, & Core Values (2025) of Ono Pharmaceutical Co., Ltd.

An Overview of Ono Pharmaceutical Co., Ltd.

General Overview of Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., founded in 1717, has a long-standing history in the pharmaceutical industry. The company is headquartered in Osaka, Japan, and has evolved from its roots as a traditional medicine provider to a leader in biopharmaceuticals. Ono is renowned for its dedication to drug discovery and development, particularly in immunology and oncology.

As of 2024, Ono's product portfolio includes Opdivo (nivolumab), an immune checkpoint inhibitor used in cancer treatment, which has significantly contributed to its sales. The company also offers Regeneron’s Eylea, along with other therapeutic agents targeting various diseases. In 2023, Ono reported sales of approximately ¥450 billion (about $4 billion), marking a substantial growth trajectory.

Company's Financial Performance in the Latest Financial Reports

Ono Pharmaceutical's latest financial report showcased record-breaking revenue, particularly driven by its flagship product, Opdivo. The company reported a revenue increase of 12% year-over-year in the latest quarter, translating to ¥128 billion (around $1.15 billion) in sales from Opdivo alone during the first half of 2024.

Additionally, Ono has seen growth in international markets, especially in the United States and Europe, contributing to 30% of its total revenue. The following table summarizes key financial data from the latest reporting period:

Introduction to Ono as a Leader in the Industry

Ono Pharmaceutical Co., Ltd. stands out as one of the leaders in the pharmaceutical industry, recognized for its innovative drug development and strong market presence. Its commitment to research and development, with an investment of over 20% of its revenue back into R&D, positions Ono at the forefront of medical advancements.

Furthermore, Ono's strategic partnerships with global companies and research institutions enhance its capabilities and accelerate the development of breakthrough therapies. Investors interested in understanding the factors behind Ono's success are encouraged to explore further insights into its operations and market strategies.

Mission Statement of Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. Mission Statement

Ono Pharmaceutical Co., Ltd. emphasizes its commitment to 'creating innovation in healthcare' through its mission statement. This guiding principle is pivotal in aligning the company's strategies, organizational culture, and corporate objectives with its long-term goals. As of 2024, the company continues to focus on advancing healthcare through innovative research and high-quality pharmaceutical products.

Core Component 1: Innovation

Innovation serves as the cornerstone of Ono Pharmaceutical's mission. The company invests heavily in research and development, allocating approximately 20.3% of its total revenue towards R&D activities in the fiscal year 2023. This commitment has resulted in a robust pipeline with over 22 new drug candidates in various stages of development, targeting diseases like cancer and autoimmune disorders.

Core Component 2: Quality

Delivering high-quality products is paramount for Ono Pharmaceutical. The company maintains a Quality Management System compliant with ISO 9001 standards. In 2023, it achieved a product recall rate of less than 0.1%, significantly lower than the industry average of 1%. This statistic underscores Ono's dedication to ensuring the safety and efficacy of its pharmaceutical offerings.

Core Component 3: Patient Focus

Ono Pharmaceutical prioritizes patient outcomes in its mission statement. To reinforce this commitment, it has established partnerships with healthcare providers and patient advocacy groups. In 2023, the company launched Patient Support Programs that reached over 30,000 patients, providing them with essential resources and information about treatment options.

Vision Statement of Ono Pharmaceutical Co., Ltd.

Innovative Research and Development

Ono Pharmaceutical Co., Ltd. places a strong emphasis on innovative research and development as a core component of their vision statement for 2024. In fiscal year 2022, the company allocated approximately ¥44.3 billion ($395 million) towards R&D efforts, which is roughly 21% of total revenues. This investment showcases their commitment to expanding their pipeline, focusing on oncology, immunology, and regenerative medicine.

Global Expansion

A pivotal aspect of Ono's vision is to enhance its global footprint. As of 2023, 30% of Ono's net sales were generated from international markets, particularly in the United States and Europe. The company aims to increase this percentage to 50% by 2025, leveraging partnerships and collaborations with key global players, including ImmunoGen and Takeda Pharmaceutical.

Patient-Centric Approaches

Ono Pharmaceutical's vision emphasizes a patient-centric approach in all its endeavors. In 2022, they reported a 95% patient satisfaction rate regarding their oncology treatments. This percentage reflects their focus on addressing unmet medical needs and enhancing the quality of life for patients. The company is also extending its patient access programs, aiming to provide treatment solutions to over 1 million patients by the end of 2024.

Sustainable Practices

Sustainability is integral to Ono's vision as well. In 2023, they reported a 50% reduction in CO2 emissions from their operations compared to 2019 levels. The company's goal is to achieve carbon neutrality by 2030, underscoring their commitment to environmental stewardship. Initiatives include eco-friendly packaging and energy-efficient manufacturing processes.

Collaborative Ecosystem

Ono is also focused on fostering collaboration within the pharmaceutical ecosystem. In 2023, they entered into 12 strategic alliances aimed at co-developing innovative therapies, enhancing research capabilities, and sharing resources. This collaborative approach is expected to accelerate the delivery of new medicines and expand their therapeutic reach.

Core Values of Ono Pharmaceutical Co., Ltd.

Innovation

Ono Pharmaceutical Co., Ltd. emphasizes innovation as a core value, driving the development of new treatments and therapies. In 2024, the company invested ¥43 billion in R&D, focusing on innovative drug development.

Examples of this commitment include:

• Collaboration with 15 academic institutions to enhance research initiatives.
• The launch of ABP 215, a biosimilar drug, which expanded its oncology portfolio.
• Over 300 patents filed globally in the past year reflecting its innovative advancements.

Integrity

Integrity is foundational to Ono's operations, ensuring ethical practices in all areas. The company adheres to stringent compliance standards and has maintained a 100% adherence rate to regulatory requirements in its latest audits.

Demonstrations of integrity include:

• Annual employee ethics training, with 95% participation rate.
• Transparent reporting of clinical trial results, with all results made publicly available.
• A whistleblower program that has processed 10 reports with no retaliation incidents recorded.

Patient-Centricity

Ono's core value of patient-centricity reflects its dedication to improving patients' lives. In 2023, the company launched a new patient assistance program that reached over 12,000 patients in need.

Specific initiatives include:

• Partnership with patient advocacy groups to ensure that patient voices are heard in drug development.
• Introduction of the Ono Patient Support Program, providing resources and support for therapy adherence.
• Conducting over 50 patient satisfaction surveys annually to gather feedback on its services.

Collaboration

Collaboration is a key value at Ono, fostering partnerships with various stakeholders. In 2023, the company formed strategic alliances with 10 major pharmaceutical companies to enhance drug development efforts.

Examples include:

• The establishment of a joint venture focusing on regenerative medicine with a leading biotech firm, resulting in a combined investment of ¥15 billion.
• Engagement with over 200 researchers globally through collaborative research initiatives.
• Participation in international forums, contributing findings from 5 major clinical trials.